LiverLearning®: 2018 Webinar: Portal Vein Thrombosis in Cirrhosis: Causes and Consequences

This webinar will focus on the concept of coagulation in cirrhosis; pathophysiology, concept of a rebalanced coagulation state in cirrhosis and the consequences such as portal vein thrombosis. The management of PVT will be discussed.Andres Cardenas (Moderator) Dr. Andrés Cárdenas is currently a Consultant and Clinical Professor of the Institute of Digestive Diseases and Metabolism at Hospital Clinic and University of Barcelona.

The histone methyltransferase Suv39h2 contributes to nonalcoholic steatohepatitis in mice

Zhiwen Fan, Luyang Li, Min Li, Xinjian Zhang, Chenzhi Hao, Liming Yu, Sheng Zeng, Huihui Xu, Mingming Fang, Aiguo Shen, Thomas Jenuwein, Yong Xu – 28 February 2017 – Uncontrolled inflammatory response highlights the central theme of nonalcoholic steatohepatitis (NASH), a growing global pandemic. Hepatocytes and macrophages represent two major sources of hepatic inflammation during NASH pathogenesis, contributing to excessive synthesis of proinflammatory mediators. The epigenetic mechanism that accounts for the activation of hepatocytes and macrophages in this process remains obscure.

Prognostic effect of transarterial chemoembolization–induced complete pathological response in patients undergoing liver resection and transplantation for hepatocellular carcinoma

Woo‐Hyoung Kang, Shin Hwang, Gi‐Won Song, Young‐Joo Lee, Ki‐Hun Kim, Chul‐Soo Ahn, Deok‐Bog Moon, Dong‐Hwan Jung, Gil‐Chun Park, Sung‐Gyu Lee – 27 February 2017 – Transarterial chemoembolization (TACE)–induced complete pathological response (CPR) is known to improve postresection outcomes of hepatocellular carcinoma (HCC). We aimed to assess the prognostic effects of CPR after preoperative TACE for HCC in patients who underwent hepatic resection (HR) or liver transplantation (LT). The clinical outcomes of patients showing CPR after HR (n = 110) or LT (n = 233) were analyzed.

Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals

Pamela S. Belperio, Troy A. Shahoumian, Larry A. Mole, Lisa I. Backus – 27 February 2017 – Reactivation of hepatitis B virus (HBV) has been reported in hepatitis C virus–infected individuals receiving direct‐acting antiviral (DAA) therapy. The overall risk among patients with current or prior HBV infection in the context of DAA treatment is unknown. The aim of this evaluation was to identify and characterize HBV reactivation among veterans treated with oral DAA therapy. This retrospective evaluation included 62,290 hepatitis C virus–infected veterans completing oral DAA treatment.

A multicenter study to define sarcopenia in patients with end‐stage liver disease

Elizabeth J. Carey, Jennifer C. Lai, Connie W. Wang, Srinivasan Dasarathy, Iryna Lobach, Aldo J. Montano‐Loza, Michael A. Dunn, for the Fitness, Life Enhancement, and Exercise in Liver Transplantation Consortium – 27 February 2017 – Sarcopenia is associated with increased wait‐list mortality, but a standard definition is lacking. In this retrospective study, we sought to determine the optimal definition of sarcopenia in end‐stage liver disease (ESLD) patients awaiting liver transplantation (LT). Included were 396 patients newly listed for LT in 2012 at 5 North American transplant centers.

Share 35 changes in center‐level liver acceptance practices

David S. Goldberg, Matthew Levine, Seth Karp, Richard Gilroy, Peter L. Abt – 27 February 2017 – Share 35 was implemented to provide improved access to organs for patients with Model for End‐Stage Liver Disease (MELD) scores ≥ 35. However, little is known about the impact of Share 35 on organ offer acceptance rates. We evaluated all liver offers to adult patients who were ultimately transplanted between January 1, 2011 and December 31, 2015.

Subscribe to